Pomalidomide
Pomalidomide is an immunomodulatory antineoplastic agent. The chemical name is (RS)-4-Amino-2-(2,6-dioxo-piperidin-3-yl)-isoindoline-1,3-dione. It is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Primary Characteristics
It is of Synthetic origin and belongs to Isoindoles and Derivatives.
Molecular Weight: 273.24 · Non-proprietary name: Pomalidomide.
Pharmacokinetics
Absorption: Pomalidomide has an oral bioavailability is 73%.
Distribution: Pomalidomide has a volume of distribution is between 62 &138L. plasma protein binding is 12-44%.
Elimination: it is metabolised via liver, plasma half-life is 7.5-9.4, renal excretion is 73% by urine & 15% by feces.
Advertisement
Indications
Pomalidomide is primarily indicated in conditions like Multiple myeloma.
Contraindications
None recorded.
Dosage
Pomalidomide's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 0 – 4 mg | — | Every 24h | PO | for multi myeloma |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Pomalidomide is known to cause more or less tolerable side effects which are usually transient. These include Anemia, Asthenia , Back pain, Confusion, Constipation , Diarrhea, Dizziness, Fatigue, Nausea, Neutropenia, Pyrexia , tumor lysis syndrome, upper GIT infecyion.
Warnings / Precautions
Available Brands
None recorded.
Storage Conditions
Drug Classification
- 1.8.1 — Immunomodulators